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Abstract 64 
Prior comparisons of survival between dialysis and non-dialysis care for older adults with kidney 65 
failure are limited to those managed by nephrologists, and are vulnerable to lead and immortal 66 
time biases. We compared time to all-cause mortality among older adults with kidney failure 67 
treated vs not treated with chronic dialysis. We did a retrospective cohort study using linked 68 
administrative and laboratory data to identify adults aged ≥65 years in Alberta, Canada, with 69 
kidney failure (2002-2012). Kidney failure was defined by ≥2 consecutive outpatient eGFR 70 
values of <10 mL/min/1.73m2, spanning ≥90 days. We used marginal structural Cox regression 71 
to account for baseline and time-varying differences between dialysis and non-dialysis groups. 72 
838 patients met cohort inclusion criteria with 815 (97.3%) included in the inverse probability of 73 
treatment weighted cohort (mean age 79.3; 48.8% male; mean eGFR 7.8 mL/min/1.73m2). 74 
Compared to people not treated with chronic dialysis, dialysis was associated with a lower risk of 75 
death in the first 3 years of follow-up (HR 0.47; 95% CI 0.37-0.60, p<0.001), but not after 3 76 
years of follow-up. Results were robust in a number of sensitivity analyses (HR 1.35; 95% CI 77 
0.78-2.34, p=0.28). Among older adults with kidney failure, treatment with dialysis was 78 
associated with improved survival up to 3 years after reaching kidney failure. These findings 79 
provide information to support shared treatment decision-making.  80 
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Introduction  81 
Compared to their younger counterparts, older adults with advanced chronic kidney disease 82 
(CKD) experience higher morbidity1–3 and mortality,4 and are more likely to die than progress to 83 
kidney failure requiring renal replacement therapy.4–6 The majority of older adults with advanced 84 
CKD nevertheless receives or prepares to receive renal replacement therapy,7 as nearly 30% of 85 
patients initiating dialysis in North America are aged ≥75 years.8,9,10 Complicating treatment 86 
decision-making, the life expectancy of this population is limited and the impact of dialysis on 87 
survival is not clear.11 88 
Although the decision to initiate dialysis is complex, including quality of life considerations and 89 
the impact of treatment on patients and their families,12 the evidence to support the potential for 90 
dialysis to prolong survival among older adults is limited. A recent systematic review reported 91 
similar 1-year survival among older adults with kidney failure regardless of whether they 92 
received dialysis or not.13 This review, however, was based on heterogeneous studies with small 93 
numbers of patients particularly in non-dialysis groups who were managed by nephrology teams. 94 
There were also considerable differences in demographic and/or clinical characteristics (e.g. age, 95 
diabetes, other comorbidities) between those treated and not treated with dialysis, and the timing 96 
of renal replacement therapy initiation, with potential for lead-time and immortal time biases.13–97 
16 98 
Given the limited evidence regarding survival comparisons in this patient population, our 99 
research objective was to assess all-cause mortality associated with chronic dialysis versus non-100 
chronic dialysis care among older adults with kidney failure taking into account differences in 101 
baseline and time-varying patient data. We addressed the risk of lead-time bias by using a 102 
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consistent definition of sustained kidney failure for both groups and the risk of immortal time 103 
bias using a time-varying exposure. 104 
Results 105 
Patient characteristics 106 
We identified 5238 Alberta residents aged ≥65 years with kidney failure defined by sustained 107 
estimated glomerular filtration rate (eGFR) <10 mL/min/1.73m2. Following exclusion of patients 108 
who initiated dialysis on or before the index date, those who died on index date, and those with a 109 
kidney transplant, the final cohort included 838 older adults (figure 1); 500 (59.7%) received 110 
chronic dialysis and 338 (40.3%) did not (table 1).  111 
Patient characteristics after applying time-dependent weights 112 
After exclusion of 23 patients with weights outside the 1-99 percentile of the distribution 113 
(indicating low comparability), we included 481 (96%) adults who received chronic dialysis and 114 
334 (99%) adults who did not receive dialysis. The median duration between the index date and 115 
dialysis initiation was 99 (IQR 38, 254) days. Compared to patients not treated with dialysis, 116 
patients who eventually received chronic dialysis were more likely to be male (55.3% versus 117 
39.5%), younger (mean age 76.5 versus 83.3 years), treated with ACEi/ARBs (72.6% versus 118 
53.3%), and treated with statins (60.3% versus 38.9%, table 1). Patients treated with dialysis also 119 
had a lower comorbidity index (13.1% versus 24.3% with Charlson Comorbidity Index ≥7). 120 
Among those who were never treated with dialysis, 16.2% of patients had never been referred to 121 
a nephrologist. 122 
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Hazard ratio of all-cause mortality 123 
Overall 296 (88.6%) patients in the non-dialysis group (median follow-up 0.78 years, IQR 0.3, 124 
1.7 years) and 344 (71.5%) in the dialysis group (median follow-up 3.0 years, IQR 1.6, 4.5 125 
years) died. Compared to older adults with similar characteristics and not treated with dialysis, 126 
treatment with dialysis was associated with a lower risk of all-cause mortality in the first 3 years 127 
of follow-up (hazard ratio [HR] 0.47; 95% CI 0.37 to 0.60, p <0.001, table 2). Results by each 128 
year of follow-up are shown in figure 2. 129 
After the first 3 years of follow-up we found that dialysis was no longer associated with a 130 
reduction in risk of all-cause mortality (HR 1.35; 95% CI 0.78 to 2.34, p=0.283], table 2), 131 
although the number of observations was small in this second period of time: 31 patients in the 132 
non-dialysis group and 242 in the dialysis group were at risk at 3 years. Non-dialysis patients 133 
surviving past 3 years had a median decline in eGFR that was minimal at -0.36 (IQR -0.84, 0.20) 134 
mL/min/1.73m2 compared to -2.3 (IQR -6.3, 0.0) mL/min/1.73m2 in the dialysis group prior to 135 
dialysis initiation. For both time periods, there was no significant evidence of effect modification 136 
by age or level of comorbidity. 137 
Sensitivity analyses 138 
Results were similar when we excluded patients referred late or never referred to a nephrologist, 139 
and in a sub-group analysis including patients with a non-rapid decline of eGFR ≤5 140 
mL/min/1.73m2 per year in 3 years prior to index (table 2). We also obtained similar results when 141 
we used the full cohort (N=838), i.e. including patients who we excluded from main analysis due 142 
to weights outside the 1-99 percentiles of the distribution. When we used eGFR <15 143 
mL/min/1.73m2 as an alternative definition of sustained (at least 90 days) kidney failure, the 144 
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association between receipt of dialysis versus no dialysis and reduced mortality in the first three 145 
years of follow-up was also consistent (tables S1-S3). 146 
Hazard ratio of all-cause hospitalization 147 
Overall, we found the crude rate of all-cause hospitalization was higher in the dialysis than non-148 
dialysis group (2.74 [95% CI 2.60 to 2.89] versus 2.37 [95% CI 2.19 to 2.58] hospitalizations per 149 
1000 patients-days survived, respectively). The adjusted incidence rate ratio of all-cause 150 
hospitalization was 1.41 (95% CI 1.17 to 1.70, p <0.001). 151 
 152 
Discussion 153 
In this population-based cohort study of older adults with kidney failure, we found that dialysis 154 
was associated with a lower risk of death during the first 3 years following kidney failure, 155 
relative to those not treated with chronic dialysis. This relationship was not modified by age or 156 
comorbidity. However, the reduction in risk of death was no longer evident after 3 years of 157 
follow-up. These results were robust in a number of sensitivity analyses including the exclusion 158 
of patients who were late or never referred to a nephrologist. 159 
Results from previous observational studies are inconsistent.14 While some studies have shown a 160 
survival advantage associated with dialysis care,17,18 others report an attenuated or null 161 
association among patients with greater comorbidity, older age, or after adjustment in 162 
multivariate analysis.15,16,19–23 These studies, however, are limited to settings managed by 163 
nephrologists.24,25 Prior studies are also limited in their ability to control for important biases 164 
including lead-time and immortal time biases.13 Lead-time gives an illusion of survival benefit 165 
when diagnosis is identified prior to its usual clinical presentation.26 Lead-time bias is 166 
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noteworthy among patients in the non-dialysis group, as bias may arise from their identification 167 
prior to the date at which they would hypothetically initiate dialysis. We attempted to address 168 
this issue by setting a 90-day criterion to define the index date. Immortal time, on the other hand, 169 
may bias the measurement of survival times in patients who go on to receive dialysis compared 170 
to those who never receive dialysis.27 A time-varying treatment/exposure analysis was used to 171 
minimize the risk of this bias.27 172 
Our results have implications for decision-making about dialysis initiation specifically for older 173 
adults with kidney failure where the survival advantage of dialysis versus non-dialysis care is 174 
unclear given their demographic and clinical characteristics. Support of treatment decision-175 
making for older adults with kidney failure requires close monitoring of clinical information (e.g. 176 
indications for dialysis) as well as their individualized goals, expected prognosis, and benefits 177 
and harms of dialysis other than survival.28,29 Although dialysis may reduce risk of death, 178 
dialysis may also negatively impact quality of life and the burdens related to dialysis including 179 
potential for infections and vascular access issues need to be considered.30 Compared to non-180 
dialysis care, dialysis patients may spend more time in hospital31 and have a higher likelihood of 181 
death in-hospital (versus at home or in-hospice).15,31 They may also have a lower likelihood of 182 
having advance care planning and palliative care compared to their non-dialysis counterparts.15 183 
Hence, the survival information generated from this study can be used to educate patients and 184 
providers to support treatment decision-making when communicated in the context of the 185 
potential negative impacts of dialysis on quality of life. 186 
Previous work sheds light as to why some patients initiate dialysis while others do not. Factors 187 
such as older age, remote residence location, and cancer or metastatic cancer have been reported 188 
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to be associated with a decreased likelihood of initiating dialysis.4 In contrast the presence of 189 
diabetes and severe proteinuria are associated with an increased likelihood of initiating dialysis.4 190 
Further, a systematic review of qualitative studies32 reported four major themes central to 191 
treatment decision making: the thoughts, feelings, and attitudes of patients and their families 192 
confronting CKD as a life-threatening illness; the perceived lack of choice in treatment decision-193 
making; the ways in which patients and their carers learnt about treatment options; and the 194 
influences from patients’ desire to maintain their pre-existing lifestyle and opinions of family 195 
and friends. 196 
Our study has a number of strengths including its population-based design in a setting with 197 
universal access to health care. Also, our study was strengthened by its methodological rigor in 198 
addressing treatment-selection, lead-time, and immortal time biases in the examination of 199 
survival between dialysis and non-dialysis care groups. 200 
The results from our study nevertheless need to be considered in the context of its limitations. 201 
We cannot exclude the possibility of residual confounding given our observational design, and 202 
were unable to account for potential confounders at baseline including indication for dialysis 203 
initiation comprising symptoms or signs attributable to kidney failure (such as pruritus); 204 
nutritional status; or frailty.33 We did not have information on patient values or preferences,34 or 205 
on disease severity for most comorbidities as these data are not available in our administrative 206 
data sources. However, we were able to include severity of liver disease (mild or 207 
moderate/severe) and severity of kidney disease by taking into account eGFR (progression of 208 
eGFR per year) and proteinuria (normal/mild, moderate, or severe). We were also able to 209 
identify clinically important demographic characteristics and a wide range of comorbidities, 210 
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given that an increased number of comorbidities suggests increased risk of poor health outcomes 211 
and complexity of clinical management.35 The generalizability of the findings is hence limited to 212 
patients with baseline characteristics included in the study, notably individuals with lower rates 213 
of eGFR progression and lower levels of comorbidity. While the feasibility of a randomized 214 
control trial remains to be determined, carefully designed observational studies addressing key 215 
methodological issues such as selection and measurement biases36 may remain the only means to 216 
address this study question. We attempted to enhance comparability by creating a synthetic 217 
sample of weighted observations in which dialysis treatment was independent of covariates 218 
measured at baseline and over time. This method is recommended when time-varying analysis 219 
methods are used.37 We cannot with complete certainty remove lead-time bias as information on 220 
clinical symptoms and signs for dialysis initiation was not available. However, we aimed to 221 
minimize lead time bias by adopting a conservative and recommended definition of kidney 222 
failure.33 Finally, we reported the rate of hospitalizations but future work is required to examine 223 
causes of hospitalizations and lengths of stay as in other studies.31 224 
In conclusion, we found that dialysis was associated with a reduced risk of death compared to 225 
non-dialysis only within the first 3 years following onset of kidney failure among older adults. 226 
The association between dialysis initiation and quality of life or health benefit overall for older 227 
adults remains to be determined. These findings can be used to support shared clinical decision-228 
making within nephrology and primary care settings when managing older adults with kidney 229 
failure. Future prospective cohort studies are required to identify older patients that benefit from 230 
dialysis initiation in terms of not only survival, but also quality of life. 231 
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Methods 232 
Study population and cohort definition 233 
We did a retrospective cohort study using population-based laboratory and administrative data 234 
from Alberta, Canada.38 Provincial administrative and laboratory data were linked using unique 235 
Alberta Personal Health Numbers to assemble a study cohort of Alberta residents that were ≥65 236 
years of age and identified as having kidney failure between May 15, 2002 and December 31, 237 
2012. The study end date was December 31, 2013 to allow for at least 1 year of follow-up. 238 
We defined kidney failure by a series of ≥2 consecutive outpatient eGFR measurements of <10 239 
mL/min/1.73m2, calculated using the CKD-EPI equation,39 spanning at least 90 days. The first 240 
eGFR after the 90-day period was used to define the index date for patients (regardless of 241 
treatment status) to minimise lead-time bias (figure 3). We chose eGFR <10 mL/min/1.73m2 to 242 
define kidney failure as it reflects a level of kidney function at which patients and providers 243 
would have made a decision whether to pursue chronic dialysis or not. Others have previously 244 
used similar definitions of kidney failure.4,16,21,31,40 We found previously that the proportion of 245 
patients in Alberta starting dialysis with eGFR <10.5 mL/min/1.73m2 has increased from 74% to 246 
85% between 2004 and 2013.41 247 
We excluded patients who died on their index date as well as those treated with chronic dialysis 248 
prior to or on the index date. Patients receiving a kidney transplant at any time during the study 249 
period were excluded as they likely represent a healthier population36 and would not be 250 
considered for non-dialysis care.42  251 
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Definition of exposure 252 
The exposure of interest was chronic dialysis treatment. We identified incident chronic dialysis 253 
cases (hemodialysis or peritoneal dialysis) from provincial dialysis registries, which include 254 
information on all patients treated with chronic dialysis in Alberta.43 These chronic dialysis 255 
registries establish chronicity of dialysis treatment for kidney failure by duration >90 days as per 256 
international clinical practice guidelines, with patients who died within 90 days included if the 257 
dialysis was intended to be chronic.33,44,45 We supplemented classification of chronic dialysis 258 
with physicians’ claims using similar criteria. A priori, we used a time-varying exposure variable 259 
to characterize treatment status during follow-up to avoid immortal time bias whilst maximizing 260 
our sample size.27 We assumed that, once a patient started chronic dialysis, he or she was 261 
considered on it for the rest of the follow-up. 262 
Outcome 263 
The outcome of interest was all-cause mortality determined from the Alberta Health Registry and 264 
Alberta Vital Statistics data. We also examined all-cause hospitalization determined from the 265 
Hospital Discharge Abstracts database. We followed patients from their index date to their date 266 
of death, out-migration from the province, or study end date (December 31, 2013).  267 
Measurement of covariates 268 
We identified baseline characteristics at the index date. Demographic characteristics identified 269 
from the Alberta Health Registry file included age, sex, and First Nations status based on the 270 
Federal Indian Act.46 We used the Canadian Census (2001, 2006, and 2011 that was nearest to 271 
the index date)47 with the Statistics Canada Postal Code Conversion File48 to determine rural 272 
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location of residence, which was defined by a population size of <1000 or density <400 273 
individuals per square km outside a metropolitan area.48 274 
Diabetes49 and hypertension50 were identified from hospital discharge records and physician 275 
claims using validated algorithms. We identified other comorbidities based on the Deyo 276 
classification of Charlson comorbidities (dementia; cerebrovascular disease; myocardial 277 
infarction; congestive heart failure; peripheral vascular disease; chronic obstructive pulmonary 278 
disease; mild liver disease; moderate and severe liver disease; peptic ulcer disease; 279 
rheumatologic disease; paraplegia and hemiplegia; and cancer) using validated International 280 
Classification of Diseases (ICD), Ninth Revision and ICD-10 coding algorithms from physician 281 
claims and hospitalization data, respectively.51 At least one diagnostic code identified up to three 282 
years prior to cohort entry was used to identify these comorbidities. 283 
Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and statin use were 284 
defined as at least one prescription for these medications within the year prior to index date 285 
according to the Alberta Health drug file. We used the most recent outpatient albuminuria 286 
measurement within two years prior to the index date. Albuminuria was categorized in 287 
accordance with international guidelines as normal/mild, moderate, severe, or unmeasured, with 288 
the following types of measurement in descending order of preference: albumin to creatinine 289 
ratio (<3; 3 to 30; >30 mg/mmol or <30; 30 to 300; >300 mg/g), protein creatinine ratio (<15; 15 290 
to 50; >50 mg/mmol or <150; 150 to 500; >500 mg/g), and urine dipstick (negative or trace; 1+; 291 
≥2+).33 Rapid progression of eGFR was defined as a >5 mL/min/1.73m2 decline per year based 292 
on eGFR values within three years prior to the index date.33,52 Time-varying eGFR was defined 293 
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using the mean eGFR value over 30-day time intervals, or the most recent eGFR value if there 294 
was no creatinine measure in that interval. 295 
Statistical analysis 296 
To enhance comparability across exposure categories (receipt versus no receipt of dialysis 297 
therapy), we used a marginal structural Cox model with stabilized inverse-probability of 298 
treatment and censoring weights (IPWs) to account for the baseline covariates and for the 299 
potential time-varying confounding effect of eGFR.53 We used logistic regression to obtain 300 
treatment weights (inverse probabilities of starting dialysis therapy) and censoring weights 301 
(inverse probabilities of being uncensored) in each month interval from index date to end of 302 
follow-up. We obtained stabilized IPWs following standard approaches.54,55 After stabilization, 303 
the IPWs ranged from 0.02 to 347576, with 1st and 99th percentiles at 0.30 and 2.27. Following 304 
assessment of the distribution of the weights by visual inspection including the mean and range 305 
of stabilized weight (mean weight of 1 with small range of values represents well-balanced 306 
weights), we excluded individuals with IPWs from below and above the 1st and 99th percentiles 307 
(mean weight 0.93 [SD 0.26]). This method created a pseudo-population using IPWs by which 308 
the covariate distributions become balanced across dialysis and non-dialysis groups. The 309 
exposure-outcome association was then estimated in the weighted sample. The proportional 310 
hazards assumption was assessed graphically and using Schoenfeld residuals.56 We found a time-311 
dependent association between dialysis therapy and mortality violating the proportional hazard 312 
requirement.57 We hence examined the HR for each 1-year increase in follow-up time to identify 313 
two discrete time periods where hazards were proportional between treatment groups, namely 0 314 
to 3 years and ≥3 years (figure 3). The estimates for each time period were obtained from one 315 
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model including the time-dependent measures of association. Finally, we used interaction terms 316 
and subgroup analyses to assess for potential effect modification by age (categories 65 to 74; 75 317 
to 84; and ≥85 years)5,58 and level of comorbidity using the Charlson Comorbidity Index 318 
(including kidney disease; score <7 versus ≥7).21,59 We used the same approaches to study the 319 
risk of hospitalization, considering repeated hospital admissions within each patient. We used 320 
cluster (robust) methods to take into account event-correlation within patients.60 321 
We conducted a number of sensitivity analyses to assess the robustness of the findings. First, we 322 
limited analysis to patients seen by a nephrologist (before or after index date) and patients with 323 
>90 days between their first nephrology visit and initiation of dialysis.61 Second, we limited 324 
analysis to patients with non-rapid decline of eGFR prior to index. Third, the full weighted 325 
cohort was used, modelling exposure as time-varying, to examine the effect of dialysis on 326 
mortality after accounting for baseline covariates. Finally, we explored the association at a 327 
higher eGFR threshold for defining kidney failure (i.e. <15 mL/min/1.73m2). Also, we 328 
descriptively examined eGFR decline from index date to time of dialysis initiation (and to the 329 
last eGFR measurement in the non-dialysis group). Statistical analyses were conducted with 330 
Stata 14 software.62 Ethical approval and waiver of patient consent was granted from the 331 
Conjoint Health Research Ethics Review Board at the University of Calgary.  332 
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Figure 1 Cohort formation of older adults with kidney failure 
 
Figure 2 Hazard ratio of mortality for each 1-year increase in follow-up time.  
Note: HR=hazard ratio; CI=confidence interval 
 
Figure 3 Retrospective cohort study design 
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Table 1 Baseline characteristics of older adults with kidney failure by dialysis versus non-dialysis care in the unweighted  cohort and 
the weighted cohort 
 Unweighted cohort (N=838) Weighted cohort (N=815) 
Characteristic 
Ever treated  
with dialysis 
N=500 
Exclusively not 
treated with 
dialysis 
N=338 
Ever treated  
with dialysis 
N=481 
Exclusively not 
treated with 
dialysis 
N=334 
Male 273 (54.6) 134 (39.6) 266 (55.3) 132 (39.5) 
Mean age (SD) 76.3 (6.4) 83.2 (7.2) 76.5 (6.5) 83.3 (7.1) 
Age in years      
  65 to <75 228 (45.6) 45 (13.3) 213 (44.9) 42 (12.6) 
  75 to <85 220 (44.0) 143 (42.3) 216 (44.9) 143 (42.8) 
  ≥85 52 (10.4) 150 (44.4) 52 (10.8) 149 (44.6) 
Rural location of residence 101 (20.2) 48 (14.2) 96 (20.0) 48 (14.4) 
First Nations status 15 (3.0) 7 (2.1) 13 (2.7) 7 (2.1) 
Mean eGFR at index (SD)  7.8 (1.4) 7.7 (1.6) 7.8 (1.3) 7.7 (1.6) 
Index eGFR (mL/min/1.73m2) category      
  <4 7 (1.4)  9 (2.7) 7 (1.5) 9 (2.7) 
  4 to <6 37 (7.4)  38 (11.2) 34 (7.1) 38 (11.4) 
  6 to <8 226 (45.2) 113 (33.4) 220 (45.7) 110 (32.9) 
  8 to <10 230 (46.0) 178 (52.7) 220 (45.7) 177 (53.0) 
Mean (SD) progression of eGFR per year* -5.8 (5.0) -5.8 (6.7) -5.6 (4.6) -5.8 (6.5) 
Rapid decline of eGFR per year in 3 years prior to 
index (>5 mL/min/1.73m2 per year) 
231 (46.2) 143 (42.3) 215 (44.7) 139 (41.6) 
Medications      
  ACEi/ARBs 365 (73.0) 181 (53.6) 349 (72.6) 187 (53.3) 
  Statins 301 (60.2) 131 (38.8) 290 (60.3) 130 (38.9) 
Proteinuria category     
Normal or mild 21 (4.2) 36 (10.4) 20 (4.2) 35 (10.5) 
Moderate 43 (8.6) 36 (10.7) 41 (8.5) 36 (10.8) 
Severe 334 (66.8) 193 (57.1) 322 (66.9) 189 (56.6) 
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 Unweighted cohort (N=838) Weighted cohort (N=815) 
Characteristic 
Ever treated  
with dialysis 
N=500 
Exclusively not 
treated with 
dialysis 
N=338 
Ever treated  
with dialysis 
N=481 
Exclusively not 
treated with 
dialysis 
N=334 
Unmeasured 102 (20.4) 74 (21.9) 98 (20.4) 74 (22.2) 
Comorbidities     
Dementia 26 (5.2) 82 (24.3) 26 (5.4) 82 (24.6) 
Cerebrovascular disease 48 (9.6) 62 (18.3) 48 (10.0) 61 (18.3) 
Myocardial infarction 74 (14.8) 68 (20.1) 72 (15.0) 67 (20.1) 
Congestive heart failure 143 (28.6) 141 (41.7) 134 (27.9) 140 (41.9) 
Peripheral vascular disease 73 (14.6) 39 (11.5) 72 (15.0) 39 (11.7) 
Chronic obstructive pulmonary disease 132 (26.4) 116 (34.3) 123 (25.6) 114 (34.1) 
Mild liver disease 12 (2.4) 2 (0.6) 11 (2.3) 2 (0.6) 
Moderate/severe liver disease 1 (0.2) 2 (0.6) 1 (0.2) 2 (0.6) 
Peptic ulcer disease 32 (6.4) 23 (6.8) 30 (6.2) 23 (6.9) 
Diabetes 273 (54.6) 173 (51.2) 260 (54.1) 172 (51.5) 
Hypertension 482 (96.4) 309 (91.4) 467 (97.1) 305 (91.3) 
Rheumatologic disease 15 (3.0) 7 (2.1) 15 (3.1) 7 (2.1) 
Para/hemiplegia 9 (1.6) 1 (0.3) 8 (1.7) 1 (0.3) 
Cancer 78 (15.6) 69 (20.4) 75 (15.6) 66 (19.8) 
Metastatic solid tumor 4 (0.8) 16 (4.7) 3 (0.6) 15 (4.5) 
Days between first and index eGFR, median (IQR) 102 (93,116) 107 (95,123) 102 (93,116) 107 (95,124) 
N(%) reported unless indicated otherwise.  
SD=standard deviation; IQR=interquartile range; eGFR=estimated glomerular filtration rate in mL/min/1.73m2; 
ACEi=angiotensin-converting enzyme inhibitors; ARB=angiotensin-receptor blockers 
*Median (IQR) progression of eGFR per year: -4.6 (-7.8,-2.7) mL/min/1.73m2 for dialysis and -4.0 (-7.6,-2.2) mL/min/1.73m2 
for non-dialysis (entire cohort); -4.5 (-7.5,-2.7) mL/min/1.73m2 for dialysis and -4.0 (-7.6,-2.2) mL/min/1.73m2 for non-dialysis 
(weighted cohort) 
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Table 2 Hazard ratios of mortality from primary and sensitivity analyses for dialysis versus non-dialysis care using marginal structural 
models, by years of follow-up from onset of kidney failure defined with sustained eGFR <10 mL/min/1.73m² 
  Non-
dialysis N 
0 to 3 years ≥3 years 
Weighted cohort Dialysis HR 95% CI p-value HR 95% CI p-value 
Cohort excluding people with weights 
outside 1-99 percentile distribution 481 334 815 0.47 0.37-0.60 <0.001 1.35 0.78-2.34 0.283 
Exclude late or non-referred to 
nephrologist 461 280 741 0.51 0.40-0.66 <0.001 1.20 0.70-2.06 0.517 
Non-rapid decline of eGFR per 
year in 3 years prior to index (≤5 
mL/min/1.73m² per year) 
266 195 461 0.59 0.43-0.81 0.001 1.35 0.81-2.27 0.251 
Entire cohort without exclusions 500 338 838 0.67 0.48-0.92 0.017 1.55 0.79-3.04 0.198 
N=number of people; HR=Hazard ratio; CI=Confidence Interval; eGFR=estimated glomerular filtration rate 
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Supplementary Material 
 
Table S1 Hazard ratios of mortality from sensitivity analyses for dialysis versus non-dialysis 
care, by years of follow-up from onset of kidney failure defined with a higher eGFR threshold of 
<15 mL/min/1.73m² 
 
Table S2 In-hospital dialysis start by cohort  
 
Table S3 eGFR progression post-index date by cohort 
 
Supplementary information is available at KI Report’s website  
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